Are patients being treated with immunosuppression for ocular inflammatory disease adequately?

References

• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130(4):492-513
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Callanan D, Dugel P, et al. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina 2006(Suppl):1-16
   PubMed Web of Science ®Google Scholar
• Durrani K, Zakka FR, Ahmed M, et al. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol 2011;56(6):474-510
   PubMed Web of Science ®Google Scholar
• Barisani-Asenbauer T, Maca SM, Mejdoubi L, et al. Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients. Orphanet J Rare Dis 2012;7:57
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol 2013;23(5):705-17
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996;80(9):844-8
   PubMed Web of Science ®Google Scholar
• Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80(4):332-6
   PubMed Web of Science ®Google Scholar
• Chu DS, Johnson SJ, Mallya UG, et al. Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect 2013;3(1):64
   PubMedGoogle Scholar
• Kirzhner M, Jakobiec FA. Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis, and current management. Semin Ophthalmol 2011;26(4-5):270-7
   PubMed Web of Science ®Google Scholar
• Smith JR, Mackensen F, Rosenbaum JT. Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol 2007;3(4):219-26
   PubMedGoogle Scholar
• Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA. Ocular complications of Wegener’s granulomatosis. Ophthalmology 1983;90(3):279-90
   PubMed Web of Science ®Google Scholar
• McKibbin M, Isaacs JD, Morrell AJ. Incidence of corneal melting in association with systemic disease in the Yorkshire Region, 1995-7. Br J Ophthalmol 1999;83(8):941-3
   PubMed Web of Science ®Google Scholar
• Foster CS. Ocular manifestations of the potentially lethal rheumatologic and vasculitic disorders. J Fr Ophtalmol 2013;36(6):526-32
   PubMed Web of Science ®Google Scholar
• Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica 2004;218(4):223-36
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol 2001;119(6):841-9
   PubMed Web of Science ®Google Scholar
• Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol 2007;125(4):544-50
   PubMed Web of Science ®Google Scholar
• Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs 2011;16(2):309-22
   PubMed Web of Science ®Google Scholar
• Chiang YP, Bassi LJ, Javitt JC. Federal budgetary costs of blindness. Milbank Q 1992;70(2):319-40
   PubMed Web of Science ®Google Scholar
• Laliberte F, Bookhart BK, Vekeman F, et al. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm 2009;15(4):312-22
   PubMed Web of Science ®Google Scholar
• Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004;22(17):3524-30
   PubMed Web of Science ®Google Scholar
• Yates WB, McCluskey PJ, Wakefield D. Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy? J Ophthalmic Inflamm Infect 2013;3(1):48
   Google Scholar
• Barry RJ, Nguyen QD, Lee RW, et al. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol 2014;8:1891-911
   PubMedGoogle Scholar
• Gordon DM, McLean JM, Koteen H, et al. The use of ACTH and cortisone in ophthalmology. Am J Ophthalmol 1951;34(12):1675-86
   PubMed Web of Science ®Google Scholar
• Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 2008;92(4):455-9
   PubMed Web of Science ®Google Scholar
• LeHoang P. The gold standard of noninfectious uveitis: corticosteroids. Dev Ophthalmol 2012;51:7-28
   PubMedGoogle Scholar
• Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica 2010;224(1):46-53
   PubMedGoogle Scholar
• Vitale AT, Shulman JP, Foster CS. Corticosteroids. In: Foster CS, Vitale AT, editors. Diagnosis and Treatment of Uveitis. 2013 edition. W.B. Saunders, Philadelphia, PA; 2013;194-214
   Google Scholar
• Uchiyama E, Papaliodis GN, Lobo AM, Sobrin L. Side-effects of anti-inflammatory therapy in uveitis. Semin Ophthalmol 2014;29(5-6):456-67
   PubMed Web of Science ®Google Scholar
• Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009;68(7):1119-24
   PubMed Web of Science ®Google Scholar
• Udoetuk JD, Dai Y, Ying GS, et al. Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Ophthalmology 2012;119(8):1569-74
   PubMed Web of Science ®Google Scholar
• Castiblanco C, Foster CS. Review of systemic immunosuppression for autoimmune uveitis. Ophthalmol Ther 2014. [Epub ahead of print
   Google Scholar
• Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect 2012;2(1):21-8
   PubMedGoogle Scholar
• Pleyer U, Stubiger N. New pharmacotherapy options for noninfectious posterior uveitis. Expert Opin Biol Ther 2014;14(12):1783-99
   PubMed Web of Science ®Google Scholar
• Patel CC, Mandava N, Oliver SC, et al. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert). Retina 2012;32(3):537-42
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113(6):1020-7
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 2013;29(5):501-7
   PubMed Web of Science ®Google Scholar
• Lee K, Bajwa A, Freitas-Neto CA, et al. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis. J Ocul Pharmacol Ther 2014;15(15):2141-54
   Google Scholar
• Roda Perez E. [Case of uveitis of unknown etiology treated with nitrogen mustards]. Rev Clin Esp 1951;41(4):265-7
   PubMedGoogle Scholar
• Wong VG. Methotrexate treatment of uveal disease. Am J Med Sci 1966;251(2):239-41
   PubMed Web of Science ®Google Scholar
• Newell FW, Krill AE. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc U K 1967;87:499-511
   PubMedGoogle Scholar
• Mamo JG, Azzam SA. Treatment of Behcet’s disease with chlorambucil. Arch Ophthalmol 1970;84(4):446-50
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Rook AH, et al. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 1983;2(8344):235-8
   PubMed Web of Science ®Google Scholar
• Kruh J, Foster CS. Corticosteroid-sparing agents: conventional systemic immunosuppressants. Dev Ophthalmol 2012;51:29-46
   PubMedGoogle Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998;352(9121):35-6
   PubMed Web of Science ®Google Scholar
• Denniston AK, Dick AD. Systemic therapies for inflammatory eye disease: past, present and future. BMC Ophthalmol 2013;13:18
   PubMed Web of Science ®Google Scholar
• Lee K, Bajwa A, Freitas-Neto CA, et al. A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II. Expert Opin Biol Ther 2014;14(11):1651-66
   PubMed Web of Science ®Google Scholar
• Kruh J, Foster CS. The philosophy of treatment of uveitis: past, present and future. Dev Ophthalmol 2012;51:1-6
   PubMedGoogle Scholar
• Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm 2010;18(2):116-20
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. Bmj 2009;339:b2480
   PubMedGoogle Scholar
• Joshi L, Talat L, Yaganti S, et al. Outcomes of changing immunosuppressive therapy after treatment failure in patients with noninfectious uveitis. Ophthalmology 2014;121(5):1119-24
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009;148(4):500-9 e502.
   PubMed Web of Science ®Google Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009;116(11):2188-98 e2181.
   PubMed Web of Science ®Google Scholar
• Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010;117(3):576-84
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010;149(3):423-32; e421-422
   PubMed Web of Science ®Google Scholar
• Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010;117(2):356-65
   PubMed Web of Science ®Google Scholar
• Onal S, Foster CS, Ahmed AR. Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocul Immunol Inflamm 2006;14(6):367-74
   PubMed Web of Science ®Google Scholar
• Garcia-Geremias M, Carreno E, Epps SJ, et al. Clinical outcomes of intravenous immunoglobulin therapy in refractory uveitis. Int Ophthalmol 2015;35(2):281-5
   PubMed Web of Science ®Google Scholar
• Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol 2010;58(1):55-8
   PubMed Web of Science ®Google Scholar
• Kopplin LJ, Shifera AS, Suhler EB, Lin P. Biological response modifiers in the treatment of noninfectious uveitis. Int Ophthalmol Clin 2015;55(2):19-36
   PubMedGoogle Scholar
• Kaleemunnisha S, Sudharshan S, Biswas J. Quality of life in non-infectious uveitis patients on immunosuppressive therapy. Middle East Afr J Ophthalmol 2014;21(3):225-31
   PubMedGoogle Scholar
• Nguyen QD, Hatef E, Kayen B, et al. A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology 2011;118(1):184-90
   PubMed Web of Science ®Google Scholar
• Sreekantam S, Denniston AK, Murray PI. Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis-related cataract and cystoid macular oedema. Ocul Immunol Inflamm 2011;19(5):353-7
   PubMed Web of Science ®Google Scholar
• Ozzello DJ, Palestine AG. Factors affecting therapeutic decisions in intermediate and posterior uveitis. Am J Ophthalmol 2015;159(2):213-20; e213
   PubMed Web of Science ®Google Scholar
• de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30(6):452-70
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Wernick R. Selection and interpretation of laboratory tests for patients with uveitis. Int Ophthalmol Clin 1990;30(4):238-43
   PubMedGoogle Scholar
• Rodriguez A, Calonge M, Pedroza-Seres M, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol 1996;114(5):593-9
   PubMed Web of Science ®Google Scholar
• Agrawal R, Murthy S, Ganesh SK, et al. Cataract surgery in uveitis. Int J Inflam 2012;2012:548453
   PubMedGoogle Scholar
• Mehta S, Linton MM, Kempen JH. Outcomes of cataract surgery in patients with uveitis: a systematic review and meta-analysis. Am J Ophthalmol 2014;158(4):676-92; e677
   PubMed Web of Science ®Google Scholar
• Foster CS, Rashid S. Management of coincident cataract and uveitis. Curr Opin Ophthalmol 2003;14(1):1-6
   PubMedGoogle Scholar
• Huang G, Fang CH, Lopez SA, et al. Impact of fellowship training on research productivity in academic ophthalmology. J Surg Educ 2015;72(3):410-17
   PubMed Web of Science ®Google Scholar